McKesson heads into its August 5 earnings report with shorts continuing to retreat and options firmly tilted toward calls — a positioning picture that has grown more bullish since the prior note published July 26, not less.
Short covering has extended further. Short interest now stands at 2.8% of the free float, down another 21% on the week and 29% over the past month. That brings the absolute share count to roughly 3.4 million — well below the June peak above 4.8 million. The borrow market remains frictionless. Cost to borrow is running at just 0.45%, and availability has actually loosened further: shares available to borrow now amount to more than 95 times current short interest, up sharply from the approximately 63 times flagged a week ago. Shorts are not being squeezed out; they are choosing to leave. Options traders are pointing the same direction. The put/call ratio has drifted to 0.50, near its 52-week low of 0.50 and more than 1.3 standard deviations below its 20-day average — the clearest lean toward calls seen all year.
The bull and bear debate has a clear dividing line. Bulls point to a stock still trading roughly 10% below the Street's consensus target of $947, with Citigroup lifting its target to $1,000 just last week — the most recent analyst move, and the clearest signal that at least one bellwether firm sees meaningful re-rating potential after a 13% gain in the past month. UBS holds the highest target in the group at $1,050 with a Buy rating. Bears counter with what the ORTEX score history captures: 90-day EPS momentum collapsed from roughly 17 to near 3.5 between early June and mid-July, and the 50/200-day moving average ratio has slipped materially from the high-90s toward the low-90s. Wells Fargo's Equal-Weight rating with an $812 target — below the current price — encapsulates the skeptical case: the recent run may have overshot the near-term fundamental picture.
Insider activity adds a note of caution to the otherwise bullish positioning. CEO Brian Tyler sold roughly $13.3 million worth of shares across two transactions in June and early July, joined by the Chief Strategy Officer, Chief Legal Officer, and HR Director in disposing of stock. The trades carry a low significance score and may reflect planned selling programs, but the pattern — multiple C-suite sellers at prices well below the current $856 close — is worth noting against the backdrop of the sharp monthly rally.
The August 5 print will test whether McKesson's operating fundamentals, particularly in oncology and specialty drug distribution, have stabilized enough to justify a stock that has rerated sharply higher even as near-term EPS momentum has stalled.
See the live data behind this article on ORTEX.
Open MCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
